These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34322882)

  • 1. Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas.
    Nakao T; Matsuse M; Saenko V; Rogounovitch T; Tanaka A; Suzuki K; Higuchi M; Sasai H; Sano T; Hirokawa M; Miyauchi A; Kawakami A; Mitsutake N
    Clin Endocrinol (Oxf); 2021 Nov; 95(5):790-799. PubMed ID: 34322882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
    Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
    [No Abstract]   [Full Text] [Related]  

  • 4. Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules.
    Giorgenon TMV; Carrijo FT; Arruda MA; Cerqueira TLO; Barreto HR; Cabral JB; Silva TMD; Magalhães PKR; Maciel LMZ; Ramos HE
    Arch Endocrinol Metab; 2019; 63(2):107-112. PubMed ID: 30916166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Detecting Low Prevalence Somatic
    da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
    Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
    Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
    Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: A highly specific technique for pre-operative identification of high-risk cases.
    Hysek M; Hellgren LS; Stenman A; Darai-Ramqvist E; Ljung E; Schliemann I; Condello V; Larsson C; Zedenius J; Jatta K; Juhlin CC
    Diagn Cytopathol; 2023 Jun; 51(6):331-340. PubMed ID: 36870048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
    Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
    Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Assessment of TERT Promoter Mutation on Thyroid Core Needle Biopsies Supports Diagnosis of Malignancy and Addresses Surgical Strategy.
    Crescenzi A; Trimboli P; Modica DC; Taffon C; Guidobaldi L; Taccogna S; Rainer A; Trombetta M; Papini E; Zelano G
    Horm Metab Res; 2016 Mar; 48(3):157-62. PubMed ID: 25951319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
    Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
    Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
    Chen B; Shi Y; Xu Y; Zhang J
    Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules.
    Cohen Y; Rosenbaum E; Clark DP; Zeiger MA; Umbricht CB; Tufano RP; Sidransky D; Westra WH
    Clin Cancer Res; 2004 Apr; 10(8):2761-5. PubMed ID: 15102681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.
    Liu R; Xing M
    Endocr Relat Cancer; 2014 Oct; 21(5):825-30. PubMed ID: 25121551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
    Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
    Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter.
    Shi H; Guo LH; Zhang YF; Fu HJ; Zheng JY; Wang HX; Zhao CK; Xu HX
    Endocrine; 2020 May; 68(2):349-357. PubMed ID: 32026251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.
    Vuong HG; Altibi AMA; Duong UNP; Hassell L
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):411-417. PubMed ID: 28666074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.